ARTICLE | Deals
Deals Report: A cardiometabolic deal for Novo Nordisk and updates from BMS-Immatics, Takeda-Innate, Moderna-Carisma and more
By BioCentury Staff
September 17, 2024 1:19 AM UTC
The growing enthusiasm for ɑ particle-emitting radiopharmaceuticals has expanded from actinium-225 cancer therapies to include those carrying the shorter-lived isotope lead-212. But no major pharma had done a deal for a lead-212 program until last week, when Sanofi licensed the radioisotope’s most advanced program.
Sanofi (Euronext:SAN; NASDAQ:SNY) licensed AlphaMedix 212Pb-Dotamtate, a somatostatin receptor-targeted ɑ particle-emitting therapy from RadioMedix Inc. and Orano Med LLC, for $110 million up front and up to $242 million in milestones. …
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/653568/pair-of-radiopharma-deals-sees-sanofi-dive-into-212pb-as-itm-gets-another-177lu-program